Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

 
January 31, 2011
  
Date of Report (Date of earliest event reported)

 
ELITE PHARMACEUTICALS, INC.
  
(Exact name of registrant as specified in its charter)

 
Delaware
  
001-15697
  
22-3542636
  
(State or other jurisdiction
(Commission
  
(IRS Employer
  
of incorporation)
File Number)
  
Identification No.)
  

 
165 Ludlow Avenue, Northvale, New Jersey 07647
  
 (Address of principal executive offices)

 
(201) 750-2646
  
(Registrant’s telephone number, including area code)

 
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

Item 8.01 Other Events.
 
On February 4, 2011, the Company issued a press release announcing the approval of an Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration for 37.5 mg phentermine HCI  tablets.   On September 16, 2010, the Company had previously announced the acquisition of the ANDA for this generic product from Epic Pharma LLC (“Epic”).  The ANDA approval was granted under Epic Pharma’s name and transfer of the ANDA into Elite’s name will begin immediately.
 
A copy of the press release, dated February 4, 2011, is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
 
Item 9.01 Financial Statements and Exhibits
a) Not applicable.
b) Not applicable.
c) Not applicable.
d) Exhibits
 
Exhibit No.     Exhibit
     
99.1
  
Press Release dated February 4, 2011



SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: February 4, 2011
 
 
ELITE PHARMACEUTICALS, INC.
       
       
 
By:
/s/ Chris Dick
  
 
Name:
Chris Dick
 
Title:
President & Chief Operating Officer